FUTURE PERSPECTIVES The emergence of SGLT2 inhibitors and GLP1 receptor agonists represents a major advancement in the management of DKD
This contrasts with GLP-1 producing neurons in in the rat brain, which are glutamatergic 90
Sepesi B, Schmidt HE, Lada M, Correa AM, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Watson TJ, Swisher SG , Low DE, Hofstetter WL
Marketing unapproved drugs: The FDA issued warning letters to companies that marketed compounded GLP-1 medications with claims that went beyond what is permissible for compounded products
Numerous clinical studies have demonstrated the effectiveness of GHK-CU in hair regrowth